Butterfly Network Narrows Cash Burn and Boosts Adjusted Margins Despite Q3 Net Loss

Q3 Shows Foundational Progress as Cash Usage Hits Record Low

Butterfly Network’s third quarter 2025 results signal operational progress even in a challenging environment. The company reported $21.5 million in revenue for Q3, a 5% increase year-over-year, underscoring resilience against what management called a “seasonally softer period.” More importantly, Butterfly set a new record for reduced quarterly cash burn at $3.9 million—evidence of disciplined spending and strategic realignment. Cash and cash equivalents jumped to $144.2 million as of September 30, giving the company more flexibility moving forward.

Adjusted Gross Margin Hits 63.9% Despite Inventory Write-Down

While Butterfly recorded a GAAP gross loss of $3.8 million—down from last year’s $12.2 million profit—the story is different when considering non-GAAP figures. Adjusted gross margin rose to 63.9%, up from 60% in Q3 2024, thanks to higher average selling prices and reduced amortization costs. The discrepancy stems mainly from a $17.4 million write-down in obsolete inventory, a one-off event excluded from adjusted figures. For investors tracking core business performance, this surge in adjusted margins is an important indicator of improving profitability on underlying operations.

Operational Highlights: Clinical Impact, Global Security, and AI Pipeline

Butterfly’s Q3 wasn’t just about numbers—it delivered new evidence for its value in healthcare. A study in JAMA showed the company’s Auto B-line Counter helped a New Jersey hospital save $751,537 by shortening hospital stays for patients with breathing problems. Operationally, Butterfly advanced security (ISO 27001 and global certifications), achieved a third-party FDA-cleared app launch (HeartFocus), and expanded global impact with an AI maternal health tool in Africa now pending U.S. FDA review.

Technology investments remain robust. The P5.1 chip moved to production, while sixth-generation Apollo AI chip development began—positioning Butterfly for next-gen, edge-based ultrasound and platform expansion. These moves signal intent to shift ultrasound from traditional devices to scalable, software-driven solutions.

Outlook: Guidance Reaffirmed and Operating Efficiency in Focus

Butterfly reaffirmed its full-year 2025 revenue guidance of $91–95 million (about 13% projected growth) and narrowed its adjusted EBITDA loss outlook to $32–35 million. Despite an increase in total Q3 operating expenses (up 6% to $31.4 million), the company kept expenses nearly flat when excluding stock-based compensation and other charges. Adjusted EPS improved to $(0.04) from $(0.05) a year ago, pointing to ongoing gains in core operations.

The company’s solid cash position and improved efficiency give it flexibility to pursue further R&D, global commercial expansion, and potentially weather ongoing volatility in the healthcare technology sector. However, Butterfly still posted a $34 million net loss in Q3—so turning non-GAAP improvements into sustained GAAP profitability will remain a key challenge for future quarters.

Key Takeaway: Core Business Momentum, But Path to Profitability Remains Critical

Butterfly Network’s Q3 2025 update showcases encouraging underlying momentum—higher adjusted gross margins, sharply reduced cash burn, and renewed product and AI strategy execution. The company is not without its hurdles: one-time inventory charges and widening net losses remain watchpoints. Still, with $144 million in cash and an affirmed guidance range, Butterfly has positioned itself to push forward on both financial discipline and next-generation digital health solutions.

For those tracking innovation in digital health, Butterfly’s quarterly results suggest that foundational transformation—not just device sales—is driving the company’s outlook. The question remains: Can Butterfly translate operational gains and platform progress into durable bottom-line results in 2026?

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI